Mersana Therapeutics Inc (NASDAQ:MRSN) has a beta value of 1.55 and has seen 1.6 million shares traded in the last trading session. The company, currently valued at $165.19M, closed the last trade at $1.35 per share which meant it lost -$0.07 on the day or -4.93% during that session. The MRSN stock price is -365.19% off its 52-week high price of $6.28 and 20.74% above the 52-week low of $1.07. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.06 million shares traded. The 3-month trading volume is 1.44 million shares.
The consensus among analysts is that Mersana Therapeutics Inc (MRSN) is Buy stock at the moment, with a recommendation rating of 1.40. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Sporting -4.93% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MRSN stock price touched $1.35 or saw a rise of 14.56%. Year-to-date, Mersana Therapeutics Inc shares have moved -41.81%, while the 5-day performance has seen it change -10.60%. Over the past 30 days, the shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have changed -35.10%. Short interest in the company has seen 9.11 million shares shorted with days to cover at 7.89.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
Figures show that Mersana Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -65.65% over the past 6 months, with this year growth rate of 59.46%, compared to 17.10% for the industry. Revenue growth from the last financial year stood is estimated to be 3.50%.
10 analysts offering their estimates for the company have set an average revenue estimate of 8.72M for the current quarter. 10 have an estimated revenue figure of 9.63M for the next ending quarter. Year-ago sales stood 10.65M and 7.7M respectively for this quarter and the next, and analysts expect sales will shrink by -18.20% for the current quarter and 3.50% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.93% over the past 5 years.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
Insiders own 1.36% of the company shares, while shares held by institutions stand at 99.54% with a share float percentage of 100.91%. Investors are also buoyed by the number of investors in a company, with Mersana Therapeutics Inc having a total of 159.0 institutions that hold shares in the company. The top two institutional holders are ECOR1 CAPITAL, LLC with over 19.36 million shares worth more than $86.75 million. As of 2024-03-31, ECOR1 CAPITAL, LLC held 16.055% of shares outstanding.
The other major institutional holder is VR ADVISER, LLC, with the holding of over 11.33 million shares as of 2024-03-31. The firm’s total holdings are worth over $50.75 million and represent 9.3919% of shares outstanding.
